Literature DB >> 28009431

Up-regulation of long noncoding RNA CCAL predicts poor patient prognosis and promotes tumor metastasis in osteosarcoma.

Da-Kai Zhou1, Xi-Wang Yang1, Huining Li1, Yongbo Yang1, Zhen-Jun Zhu1, Na Wu2.   

Abstract

BACKGROUND: Long noncoding RNAs (lncRNAs) play essential roles in tumor progression. Aberrant colorectal cancer-associated lncRNA (CCAL) has been found in colorectal cancer. However, the function of lncRNA CCAL in osteosarcoma (OS) remains unclear.
METHODS: Quantitative real-time PCR (qRT-PCR) was performed to measure CCAL expression in OS tissues and adjacent nontumor tissues. The correlation betweent CCAL expression and clinicopathological features and prognosis was also analyzed. In addition, the function of CCAL was further evaluated by cell proliferation, migration and invasion assays.
RESULTS: We showed that CCAL was significantly up-regulated in OS tissues compared with adjacent nontumor tissues. Increased expression of CCAL was correlated with advanced TNM stage and metastasis. Kaplan-Meier analysis demonstrated that patients with high CCAL expression had lower overall survival than those with low CCAL expression. Multivariate Cox regression analysis indicated that CCAL expression might be an independent prognostic factor for OS patients. In addition, functional assays showed that decreased CCAL expression could inhibit OS cell proliferation, migration and invasion ability.
CONCLUSIONS: Our findings suggested that CCAL plays critical roles in OS progression and could act as a therapeutic target in the treatment of OS.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28009431     DOI: 10.5301/jbm.5000240

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  10 in total

Review 1.  Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Authors:  Chongchong Wang; Juehua Jing; Li Cheng
Journal:  Invest New Drugs       Date:  2018-08-06       Impact factor: 3.850

2.  LncRNA ODRUL Contributes to Osteosarcoma Progression through the miR-3182/MMP2 Axis.

Authors:  Kun-Peng Zhu; Xiao-Long Ma; Chun-Lin Zhang
Journal:  Mol Ther       Date:  2017-07-05       Impact factor: 11.454

3.  LncRNA CCAL Promotes Angiogenesis Through Regulating the MiR-29b/ANGPTL4 Axis in Osteosarcoma.

Authors:  Shiyi Chen; Mingjia Yang; Shimin Chang
Journal:  Cancer Manag Res       Date:  2020-10-23       Impact factor: 3.989

4.  LncRNA expression and implication in osteosarcoma: a systematic review and meta-analysis.

Authors:  Ying Wang; Yuelong Huang; Peng Xiang; Wei Tian
Journal:  Onco Targets Ther       Date:  2017-11-09       Impact factor: 4.147

Review 5.  Crosstalk mechanisms between the WNT signaling pathway and long non-coding RNAs.

Authors:  Vasiliki Zarkou; Alexandros Galaras; Antonis Giakountis; Pantelis Hatzis
Journal:  Noncoding RNA Res       Date:  2018-04-12

6.  Abnormally expressed long non-coding RNAs in prognosis of Osteosarcoma: A systematic review and meta-analysis.

Authors:  Delong Chen; Haibin Wang; Meng Zhang; Shan Jiang; Chi Zhou; Bin Fang; Peng Chen
Journal:  J Bone Oncol       Date:  2018-09-22       Impact factor: 4.072

7.  lncRNA FLVCR-AS1 promotes osteosarcoma growth by targeting miR381-3p/CCND1.

Authors:  Guang Yang; Fei He; Hao Duan; Jianlin Shen; Qirong Dong
Journal:  Onco Targets Ther       Date:  2020-01-09       Impact factor: 4.147

Review 8.  The Emerging Landscape of Long Non-Coding RNAs in Colorectal Cancer Metastasis.

Authors:  Zhiming Liao; Hui Nie; Yutong Wang; Jingjing Luo; Jianhua Zhou; Chunlin Ou
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

9.  Long non-coding RNA CCAL/miR-149/FOXM1 axis promotes metastasis in gastric cancer.

Authors:  Xi Luo; Gui-Hua Wang; Zhao-Lian Bian; Xi-Wen Li; Bing-Ying Zhu; Chun-Jing Jin; Shao-Qing Ju
Journal:  Cell Death Dis       Date:  2018-09-24       Impact factor: 8.469

10.  Long Noncoding RNA CCAL Promotes Papillary Thyroid Cancer Progression by Activation of NOTCH1 Pathway.

Authors:  Ying Ye; Yanan Song; Juhua Zhuang; Saifei He; Jing Ni; Wei Xia
Journal:  Oncol Res       Date:  2018-02-22       Impact factor: 5.574

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.